Vor Bio announces updated data from Phase 1/2 VBP1-1 study

Vor Bio (VOR) announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators. The data released today included 25 patients treated with trem-cel of which 15 had received Mylotarg as of the data cut-off date of November 1, 2024. The data demonstrated: Preliminary evidence of improved relapse-free survival compared to published groups of AML patients at high risk of relapse post hematopoietic stem cell transplant. Shielding of the blood system, with maintained neutrophil and platelet counts across multiple Mylotarg doses of 0.5, 1, and 2 mg/m2. Broadened therapeutic index for Mylotarg when administered after trem-cel. Reliable engraftment, with 100% of patients achieving primary neutrophil engraftment, robust platelet recovery, and full myeloid donor chimerism at Day 28. Trem-cel continues to be manufactured with high CD33 editing efficiency